The submission of new items to CORA is currently unavailable due to a repository upgrade. For further information, please contact cora@ucc.ie. Thank you for your understanding.
Files in this item
Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition
Winfield, Hannah J.; Cahill, Michael M.; O'Shea, Kevin D.; Pierce, Larry T.; Robert, Thomas; Ruchaud, Sandrine; Bach, Stéphane; Marchand, Pascal; McCarthy, Florence O.
Date:
2018-07-09
Copyright:
© 2018 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
Full text restriction information:
Access to this article is restricted until 12 months after publication by request of the publisher.
Restriction lift date:
2020-07-09
Citation:
Winfield, H. J., Cahill, M. M., O'Shea, K. D., Pierce, L. T., Robert, T., Ruchaud, S., Bach, S., Marchand, P. and McCarthy, F. O. (2018) 'Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition', Bioorganic & Medicinal Chemistry, 26(14), pp. 4209-4224. doi: 10.1016/j.bmc.2018.07.012
Abstract:
Synthesis and biological evaluation of a series of novel indole derivatives as anticancer agents is described. A bisindolylmaleimide template has been derived as a versatile pharmacophore with which to pursue chemical diversification. Starting from maleimide, the introduction of an oxygen to the headgroup (hydroxymaleimide) was initially investigated and the bioactivity assessed by screening of kinase inhibitory activity, identifying substituent derived selectivity. Extension of the hydroxymaleimide template to incorporate substitution of the indole nitrogens was next completed and assessed again by kinase inhibition identifying unique selectivity patterns with respect to GSK-3 and CDK kinases. Subsequently, the anticancer activity of bisindolylmaleimides were assessed using the NCI-60 cell screen, disclosing the discovery of growth inhibitory profiles towards a number of cell lines, such as SNB-75 CNS cancer, A498 and UO-31 renal, MDA MB435 melanoma and a panel of leukemia cell lines. The potential for selective kinase inhibition by modulation of this template is evident and will inform future selective clinical candidates.
Show full item record
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as © 2018 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
